The Diurnal Increase in Euglobulin Fibrinolytic Activity in Women Using Oral Contraceptives and in Normal Women, and the Generation of Intrinsic Fibrinolytic Activity

Summary

The diurnal fluctuations in plasma euglobulin fibrinolytic activity in women on oral contraceptives and in normal women showed similar patterns of increase. Following inactivation of inhibitors by flufenamate the individual increases and the evening levels did not differ. The diurnal increase was related to an increase in extrinsic (tissue-type) plasminogen activator (t-PA) activity, which contributes little to the total activity of the euglobulin fraction but induces an activation of the intrinsic system.

Key words

Oral contraceptives - Menstrual cycle - Diurnal fibrinolytic activity - Extrinsic (tissue-type) plasminogen activator - Intrinsic plasminogen activators - Plasma euglobulin fibrinolytic activity

• References

• 1 Jespersen J. A study of the antithrombotic potential in women on oral contraceptives low in oestrogen. In: Clinical aspects of fibrinolysis and thrombolysis, pp 399-419 Jespersen J, Kluft C, Korsgaard O. (eds.) South Jutland University Press; Esbjerg: 1983
• 2 Jespersen J. Sequential study of plasma euglobulin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen. Gynecol Obstet Invest 1983; 15: 266-274
• 3 Brakman P, Albrechtsen OK, Astrup T. Blood coagulation, fibrinolysis, and contraceptive hormones. JAMA 1967; 199: 69-74
• 4 Brakman P, Sobrero AJ, Astrup T. Effects of different systemic contraceptives on blood fibrinolysis. Am J Obstet Gynecol 1970; 106: 187-192
• 5 Jespersen J. Venous stasis in patients with angina pectoris and myocardial infarction with particular reference to measurements of t-PA activity, antigen, inhibition and euglobulin clot lysis time. EC AT Inf Bull 1984; 2: 3-7
• 6 Johansson L, Hedner U, Nilsson IM. A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall. Acta Med Scand 1978; 203: 477-480
• 7 Stormorken H, Lund M, Holmsen I. Vessel wall activator (t-PA) as evaluated by poststasis euglobulin lysis time (PELT) in recurrent deep vein thrombosis. In: Clinical aspects of fibrinolysis and thrombolysis pp 293-309 Jespersen J, Kluft C, Korsgaard O. (eds.) South Jutland University Press; Esbjerg: 1983
• 8 Korninger C, Lechner K, Niessner H, Gössinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemostas 1984; 52: 127-130
• 9 Fearnley GR, Balmforth G, Fearnley E. Evidence of a diurnal fibrinolytic rhythm with a simple method of measuring natural fibrinolysis. Clin Sci 1957; 16: 645-650
• 10 Rosing DR, Redwood DR, Brakman P, Astrup T, Epstein SE. Impairment of the diurnal fibrinolytic response in man. Effects of aging, type IV hyperlipoproteinemia, and coronary heart disease. Circ Res 1973; 32: 752-758
• 11 Cepeläk V, Bareal R, Cepeläk R, Cepeläkovä H, Mayer O. Circadian rhythm of fibrinolysis. In: Progress in chemical fibrinolysis and thrombolysis. Vol 3, pp 571-578 Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (eds.) Raven Press; New York: 1978
• 12 Jespersen J, Astrup T. A study of the fibrin plate assay of fibrinolytic agents: Optimal conditions, reproducibility and precision. Haemostasis 1983; 13: 301-315
• 13 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
• 14 Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemostas 1979; 41: 365-383
• 15 Astrup T, Rosa AT. A plasminogen proactivator-activator system in human blood effective in absence of Hageman factor. Thromb Res 1974; 4: 609-613
• 16 Kluft C. C1-inactivator-resistant fibrinolytic activity in plasma euglobulin fraction: its relation to vascular activator in blood and its role in euglobulin fibrinolysis. Thromb Res 1978; 13: 135-151
• 17 Kluft C, Wijngaards G, Jie AF H. Intrinsic fibrinolysis: involvement of urokinase-related activity in the factor XII-independent plasminogen proactivator pathway. J Lab Clin Med 1984; 103: 408-419
• 18 Jespersen J, Kluft C. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen. Levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator. Thromb Haemostas 1985; 54: 454-459
• 19 Jespersen J, Knudsen LH, Sidelmann J. The use of evacuated glass tubes for collection of blood samples for fibrinolytic assays. Thromb Res 1982; 25: 173-176
• 20 Gram J, Jespersen J, Astrup T. The influence of a preactivation phase on euglobulin fibrinolytic activity measured by the fibrin plate method. In: Progress in fibrinolysis. Vol 7, pp 155-160 Davidson J, Donati MB, Coccheri S. (eds.) Churchill Livingstone; London: 1984
• 21 Astrup T, Jespersen J. The fibrin plate assay of fibrinolytic agents -principles and technique. In: Progress in fibrinolysis. Vol 6, pp 197-201 Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. (eds.) Churchill Livingstone; London: 1983
• 22 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator, applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
• 23 Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Progress in chemical fibrinolysis and thrombolysis. Vol 2, pp 57-65 Davidson JF, Samama M, Desnoyers PC. (eds.) Raven Press; New York: 1976
• 24 Gaffney PJ, Curtis AD. A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
• 25 Rosing DR, Brakman P, Redwood DR. et al Blood fibrinolytic activity in man. Circ Res 1970; 27: 171-184
• 26 Vessey MP. Oral contraceptives and cardiovascular disease: Some questions and answers. Br Med J 1982; 284: 615-616
• 27 Chakrabarti R, Meade TW, North WR S, Stirling Y. Fibrinolytic activity in an industrial population. In: Progress in chemical fibrinolysis and thrombolysis. Vol 3, pp 115-119 Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (eds.) Raven Press; New York: 1978
• 28 Allen RA, Kluft C, Brommer EJ P. A chronic effect of smoking on fibrinolysis. In: Progress in Fibrinolysis, pp 73-75 Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. (eds.) Churchill Livingstone; Edinburgh: 1983
• 29 Kluft C, Jie AF H. Interaction between the extrinsic and intrinsic systems of fibrinolysis. In: Progress in clinical fibrinolysis and thrombolysis. Vol 4, pp 25-31 Davidson JF, Cepeläk V, Samama MM, Desnoyers PC. (eds.) Churchill Livingstone; Edinburgh: 1979
• 30 Jespersen J, Kluft C. Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle. Thromb Haemostas 1986; 55: 388-389
• 31 Kluft C, Verheijen JH, Rijken DC, Chang GT G, Jie AF H, Onkelinx C. Diurnal fluctuations in the activity of the fast-acting t-PA inhibitor. In: Progress in fibrinolysis. Vol 7, pp 117-119 Davidson JF, Donati MB, Coccheri S. (eds.) Churchill Livingstone; Edinburgh: 1985